The Northwestern Cancer Prevention Consortium (NCPC) started in 2003 under Ray Bergan, MD, funded through a contract with the National Cancer Institution Division of Cancer Prevention. The program was renewed in 2012, with Lifang Hou, MD, PhD as the Consortium's Co-Principal Investigator. In 2015, Seema Khan MD, MPH took over as the Consortium's Principal Investigator. Northwestern is one of five NCI DCP Consortia Lead Organizations in the United States and will be renewed in 2019. The current 2012-2019 Consortium consists of ten trials.

NCPC programs conduct phase 0, phase I, and phase II trials related to cancer prevention. The trials usually: 

  • study people in high-risk categories for certain types of cancer (colorectal adenoma, BRCA+, liver cirrhosis)

  • are placebo-controlled

  • enroll between 15 and 150 participants

  • have treatment phase that lasts between 1 and 6 months

  • are completed within two years

Content on NUcancerprevention.org is a courtesy from the Northwestern Cancer Prevention Consortium at Northwestern University. While we strive to maintain the most current and up to date information possible, NCPC does not guarantee accuracy, completeness, or relevance of the information supplied. The thoughts, views, and information found here do not necessarily reflect the views of Northwestern University or Northwestern Medicine. 

©2023 by Northwestern Cancer Prevention Consortium.